When researchers combined clinical features with BRAF mutant allele fraction, patients could be divided into 3 risk groups that were significantly associated with survival.
The results suggest a link, but more research is needed.
Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.
Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).
Results from the KEYNOTE-061 were presented at ESMO World GI 2018.
The IMblaze370 trial did not meet the primary endpoint.
Researchers identified potential targets for a companion diagnostic tests using poly-ligand profiling (PLP) to determine which patients with locally advanced or metastatic pancreatic cancer may benefit from gemcitabine plus evofosfamide.
Prior to this study, there were no conclusive data directly comparing these regimens.
A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.
Please login or register first to view this content.
